Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease
Patrick S. Parfrey,Robert N. Foley,Barbara H. Wittreich,Daniel J. Sullivan,Martin J. Zagari,Dieter Frei +5 more
Reads0
Chats0
TLDR
Overall adverse event rates were similar in both target groups; higher rates of skeletal pain, surgery, and dizziness were seen in the lower target group, and headache and cerebrovascular events wereseen in the higher target group.Abstract:
It is unclear whether physiologic hemoglobin targets lead to cardiac benefit in incident hemodialysis patients without symptomatic heart disease and left ventricular dilation. In this randomized, double-blind study, lower (9.5 to 11.5 g/dl) and higher (13.5 to 14.5 g/dl) hemoglobin targets were generated with epoetin α over 24 wk and maintained for an additional 72 wk. Major eligibility criteria included recent hemodialysis initiation and absence of symptomatic cardiac disease and left ventricular dilation. The primary outcome measure was left ventricular volume index (LVVI). The study enrolled 596 patients. Mean age, duration of dialysis therapy, baseline predialysis hemoglobin, and LVVI were 50.8 yr, 0.8 yr, 11.0 g/dl, and 69 ml/m 2 , respectively; 18% had diabetic nephropathy. Mean hemoglobin levels in the higher and lower target groups were 13.3 and 10.9 g/dl, respectively, at 24 wk. Percentage changes in LVVI between baseline and last value were similar (7.6% in the higher and 8.3% in the lower target group) as were the changes in left ventricular mass index (16.8 versus 14.2%). For the secondary outcomes, the only between-group difference was an improved SF-36 Vitality score in the higher versus the lower target group (1.21 versus −2.31; P = 0.036). Overall adverse event rates were similar in both target groups; higher ( Pread more
Citations
More filters
Book ChapterDOI
Current and Novel Drugs for Management of Anemia
TL;DR: This chapter provides a broad overview of various therapies used to treat anemia developing as a result of the inadequate generation of red blood cells.
Journal ArticleDOI
Naturally nonanemic dialysis patients: Who are they?
Murvet Yilmaz,Fatih Kircelli,Ayse Serra Artan,Ozgur Akin Oto,Gulay Asci,Kutay Gunestepe,Ali Basci,Ercan Ok,Mehmet Sukru Sever +8 more
TL;DR: Various features of naturally (with no ESA usage) nonanemic patients may be useful for defining several factors in the pathogenesis of anemia.
Journal Article
eHealth Services for the European Reference Network on Rare Anaemias (eENERCA).
Zinonas C. Antoniou,Eirini C. Schiza,Kleanthis C. Neokleous,Michael Angastiniotis,Constantinos S. Pattichis,Christos N. Schizas +5 more
TL;DR: An electronic registry system for the purposes of the eENERCA for rare congenital conditions that require lifelong follow up and treatment that will serve as an epidemiological tool to improve the management of patient services and ultimately improve patient care.
Original Investigation Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) Placebo Arm
Hicham Skali,Julie Lin,Marc A. Pfeffer,Chao-Yin Chen,Mark E. Cooper,John Mcmurray,Allen R. Nissenson,Giuseppe Remuzzi,Patrick S. Parfrey,Nairne Scott-Douglas,Ajay K. Singh +10 more
TL;DR: In this paper, the authors describe the natural history of hemoglobin (Hb) level trends in contemporary patients with anemia, chronic kidney disease (CKD), and type 2 diabetes mellitus.
Journal ArticleDOI
Revisiting the treatment of anemia in the setting of chronic kidney disease, hematologic malignancies, and cancer: perspectives with opinion and commentary
Franco Musio,Franco Musio +1 more
TL;DR: Commentary is made supporting more liberal use of these agents and strongly suggesting that the current underlying treatment ‘pendulum’ has perhaps shifted too far to the ‘under-treatment’ side in many cases.
References
More filters
Journal ArticleDOI
Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements.
TL;DR: The survey shows significant interobserver and interlaboratory variation in measurement when examining the same echoes and indicates a need for ongoing education, quality control and standardization of measurement criteria.
Journal ArticleDOI
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
Anatole Besarab,W K Bolton,J K Browne,Joan C. Egrie,Allen R. Nissenson,D M Okamoto,Steve J. Schwab,David A. Goodkin +7 more
TL;DR: In patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.
Journal ArticleDOI
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
Robert N. Foley,Patrick S. Parfrey,Patrick S. Parfrey,John D. Harnett,John D. Harnett,Gloria M. Kent,Gloria M. Kent,Christopher J. Martin,Christopher J. Martin,David C. Murray,David C. Murray,Paul E. Barre,Paul E. Barre +12 more
TL;DR: It is concluded that clinical and echocardiographic cardiovascular disease are already present in a very high proportion of patients starting ESRD therapy and are independent mortality factors.
Journal ArticleDOI
The RAND-36 measure of health-related quality of life
Ron D. Hays,Leo S. Morales +1 more
TL;DR: This paper provides example applications of the RAND-36 cross-sectionally and longitudinally, provides information on what a clinically important difference is for the Rand-36 scales, and provides guidance for summarizing theRand-36 in a single number.
Journal ArticleDOI
Development of the Kidney Disease Quality of Life (KDQOL) Instrument
TL;DR: The KDQOLTM was administered to 165 individuals with kidney disease, sampled from nine different outpatient dialysis centres located in Southern California, the Northwest, and the Midwest, and provided support for the reliability and validity of the measure.
Related Papers (5)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer,Emmanuel A. Burdmann,Chao-Yin Chen,Mark E. Cooper,Dick de Zeeuw,Kai-Uwe Eckardt,Jan Feyzi,Peter Ivanovich,Reshma Kewalramani,Andrew S. Levey,Eldrin F. Lewis,Janet B. McGill,John J.V. McMurray,Patrick S. Parfrey,Hans-Henrik Parving,Hans-Henrik Parving,Giuseppe Remuzzi,Ajay K. Singh,Scott D. Solomon,Robert D. Toto +19 more